Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: A case report.
PR3-ANCA
alveolar haemorrhage
autoimmunity
hypertransaminasaemia
immunology
Journal
Modern rheumatology case reports
ISSN: 2472-5625
Titre abrégé: Mod Rheumatol Case Rep
Pays: England
ID NLM: 101761026
Informations de publication
Date de publication:
19 06 2023
19 06 2023
Historique:
received:
29
09
2022
revised:
21
12
2022
accepted:
11
01
2023
medline:
21
6
2023
pubmed:
26
1
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
We here report the first case of anti-proteinase 3-positive anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis following the severe acute respiratory syndrome coronavirus 2 Pfizer-BioNTech vaccine presenting with prominent liver involvement and alveolar haemorrhage. Two weeks after vaccination, a 49-year-old man developed inflammatory arthralgias and hypertransaminasaemia. Two months later, fever and haemoptysis appeared; the patient tested positive for anti-proteinase 3 autoantibodies. High-dose steroids and rituximab were started, and complete remission was achieved. Systemic autoimmune diseases, including ANCA-associated vasculitis, should always be considered in the differential diagnosis of hypertransaminasaemia, especially when the clinical context is suspicious.
Identifiants
pubmed: 36695552
pii: 7005160
doi: 10.1093/mrcr/rxad005
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
COVID-19 Vaccines
0
Myeloblastin
EC 3.4.21.76
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
440-443Informations de copyright
© Japan College of Rheumatology 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.